66.06
-2.26 (-3.31%)
| Previous Close | 68.32 |
| Open | 68.95 |
| Volume | 727,081 |
| Avg. Volume (3M) | 688,018 |
| Market Cap | 2,788,663,552 |
| Price / Sales | 7.91 |
| Price / Book | 7.46 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | -44.91% |
| Operating Margin (TTM) | -33.55% |
| Diluted EPS (TTM) | -2.70 |
| Quarterly Revenue Growth (YOY) | 183.70% |
| Total Debt/Equity (MRQ) | 21.13% |
| Current Ratio (MRQ) | 5.57 |
| Operating Cash Flow (TTM) | -65.89 M |
| Levered Free Cash Flow (TTM) | -36.41 M |
| Return on Assets (TTM) | -16.05% |
| Return on Equity (TTM) | -33.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tarsus Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 4.0 |
| Average | -0.63 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.25% |
| % Held by Institutions | 110.77% |
| 52 Weeks Range | ||
| Median | 88.00 (33.21%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Oct 2025 | 88.00 (33.21%) | Buy | 71.19 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Tarsus to Participate in Upcoming Investor Conferences |
| 06 Aug 2025 | Announcement | Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements |
| 30 Jul 2025 | Announcement | Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |